ReviewThe Journal of pharmacology and experimental therapeutics2016
Could Biomarkers Direct Therapy for the Septic Patient?
Review in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- The effects of hemoadsorption in patients with sepsis-associated persistent severe AKI who require CRRT: A prospective, randomized controlled pilot study.Annals of intensive care · 2026Article
- Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.Clinical pharmacokinetics · 2022Review
- Clinical phenotypes of acute kidney injury are associated with unique outcomes in critically ill septic children.Pediatric research · 2021Observational
- Detection of Early Cytokine Storm in Patients with Septic Shock After Abdominal Surgery.Journal of translational internal medicine · 2020Article
- Physiology and technology for the ICU in vivo.Critical care (London, England) · 2019Review
- Inflammation and Depression: A Nervous Plea for Psychiatry to Not Become Immune to Interpretation.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids.Cell death and differentiation · 2019Review
- Identification of a transcriptome profile associated with improvement of organ function in septic shock patients after early supportive therapy.Critical care (London, England) · 2018Observational
- Female mice exhibit less renal mitochondrial injury but greater mortality using a comorbid model of experimental sepsis.Internal medicine review (Washington, D.C. : Online) · 2018Article
- Metabolomics as a Driver in Advancing Precision Medicine in Sepsis.Pharmacotherapy · 2017Review
- A path to precision in the ICU.Critical care (London, England) · 2017Review
- Rolipram Improves Outcome in a Rat Model of Infant Sepsis-Induced Cardiorenal Syndrome.Frontiers in pharmacology · 2017Article
- Innovation Management? Orienting Sepsis R&D and Technology Transfer Towards Stratified Medicine.EBioMedicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Sepsis is a serious medical condition caused by a severe systemic inflammatory response to a bacterial, fungal, or viral infection that most commonly affects neonates and the elderly. Advances in understanding the pathophysiology of sepsis have resulted in guidelines for care that have helped reduce the risk of dying from sepsis for both children and older adults. Still, over the past three decades, a large number of clinical trials have been undertaken to evaluate pharmacological agents for sepsis. Unfortunately, all of these trials have failed, with the use of some agents even shown to be harmful. One key issue in these trials was the heterogeneity of the patient population that participated. What has emerged is the need to target therapeutic interventions to the specific patient's underlying pathophysiological processes, rather than looking for a universal therapy that would be effective in a "typical" septic patient, who does not exist. This review supports the concept that identification of the right biomarkers that can direct therapy and provide timely feedback on its effectiveness will enable critical care physicians to decrease mortality of patients with sepsis and improve the quality of life of survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.